Latest Articles
-
Abbott Has Set Itself Up For A Good Year Ahead
Abbott Labs (NYSE:ABT) recently released its Q4’17 earnings, and the stock jumped nearly 5% on account of better than expected results. One big takeaway from the earnings is that the skepticism around Abbott’s acquisitions of St Jude...
-
Why Abbott’s Stock Has Rallied By 40% This Year
Abbott Labs (NYSE:ABT) has seen its stock gain nearly 40% this year. Interestingly, there generally weren’t specific events that drove a significant increase in the price. The stock rally has continued throughout the year, which suggests t...
-
Abbott’s Generic Pharmaceuticals Business To Continue Growth Trajectory Led By Emerging Markets
The generic pharmaceuticals business has been trending well for Abbott Labs (NYSE:ABT) for some time now. It accounts for around 15% of the company’s value, according to our estimates. In Q3 2017, the segment saw double-digit growth in rev...
-
Price Estimate For Abbott Labs Upgraded To $49
We have revised our price estimate for Abbott Labs’ (NYSE:ABT) stock upwards to $49 in light of its recently announced third quarter results. On the plus side, the company posted impressive operational growth in the Pharmaceuticals, Diagn...
-
Abbott Labs Will Get Bigger With Freestyle Libre Flash Approval In The U.S.
The U.S. FDA recently approved Abbott Labs’ (NYSE:ABT) new blood glucose monitoring system – Freestyle Libre Flash. While this is a meaningful development for the company, it was expected. Abbott already markets the device in Europe...
-
Abbott’s Investors Eying The Value From Acquisitions
Abbott Labs (NYSE:ABT) recently released its Q2 2017 earnings, and investors appear to be feeling positive about the company’s recent acquisitions and the long-term value they may create. It appears that legal battles and FDA notices are t...
-
What To Watch For In Abbott’s Q2 Earnings
Abbott Labs (NYSE:ABT) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. First, Abbott’s nutritional business has suffered some headwinds in China due to weakness in the country’s pediatric nu...
-
What If St. Jude Medical Acquisition Doesn’t Pan Out For Abbott?
Abbott Labs (NYSE:ABT) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. St. Jude Medical does plug some gaps in Abbott’s portfolio, and the cost syne...
-
No Surprises In Abbott’s Earnings, But Investors Need To Be Convinced Of Value Of Acquisitions
Abbott Labs (NYSE:ABT) recently reported its Q1 2017 earnings and, as expected, the primary trends from previous quarters persisted. The company’s nutritional business continued to struggle in China in the wake of new safety regulations, ...
-
Abbott Labs: What To Look For In Q1 Earnings
Abbott Labs (NYSE:ABT) will report its Q1 2017 earnings on April 19. We believe that some of the key trends observed in the previous quarter are likely to continue. Our primary concern is Abbott’s nutritional segment’s performance in...
-
Nutritional Segment Subdues Abbott’s Q4’16 Growth, But Future Growth Prospects Remain Strong
Abbott Laboratories (NYSE: ABT) reported its results for Q4 2016 on January 25th. The company’s sales in the quarter grew by 2.8 percent on a reported basis and 3.8 percent on an operating basis. Abbott’s results in the quarter were s...
-
Abbott Labs Earnings Preview: Nutritional Segment To Drag Down Overall Growth
Abbott Labs (NYSE: ABT) is set to announce its Q4’16 results on January 25th. The company likely saw a tepid revenue growth in the quarter because of a weaker performance of its pediatric nutrition business in China. Going by the consensus...
-
Dark Cloud And Silver Linings: Abbott Q3’16 Earnings
Abbott Labs (NYSE: ABT) reported its Q3’16 earnings on October 19th. The results for the quarter are in some ways a prologue for the next few quarters. The company reported weakness in nutrition business, Abbott’s largest segment. Going fo...
-
Abbott Earnings Preview: Solid Performance Expected Across Its Segments
Abbott Labs (NYSE: ABT) is set to report its Q3’16 earnings on October 19 th . The company beat street estimates in the second quarter, resulting in increase in its stock price. But over the last couple of months, Abbott’s shares have taken a bea...
-
Abbott’s Catch 22 With Alere
In February this year, Abbott (NYSE: ABT) announced that it had entered into definitive agreement with Alere (NYSE: ALR) to acquire it for $56 per share, or $5.8 billion. Abbott then had over $6.1 billion in cash & equivalents after hiving-o...
